{"id":242809,"date":"2026-09-11T09:46:09","date_gmt":"2026-09-11T04:16:09","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=242809"},"modified":"2026-09-11T09:46:09","modified_gmt":"2026-09-11T04:16:09","slug":"corona-remedies-share-price","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/corona-remedies-share-price\/","title":{"rendered":"Corona Remedies Share Price in Focus After ChrysCapital Affiliate Sells 4% Stake"},"content":{"rendered":"

Sepia Investments sells 24.85 lakh shares (4.06%) at Rs 2,050.32\/share for Rs 509.6 crore. SBI MF buys 2.51%, Amundi buys smaller stake.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

The Corona Remedies share price is in focus after Sepia Investments, an affiliate of private equity firm ChrysCapital, sold 24.85 lakh shares representing a 4.06 percent stake in the company for Rs 509.6 crore at Rs 2,050.32 per share. This transaction was part of Sepia Investments’ total 12.68 percent stake in Corona Remedies as of June 2026. Of the shares sold, SBI Mutual Fund acquired a 2.51 percent stake for Rs 315.7 crore, while Amundi Funds Asia Equity Concentrated bought a smaller stake for Rs 63.96 crore, both at around the same price, keeping the Corona Remedies share price transaction largely orderly.<\/p>\n<\/div>\n

The Corona Remedies<\/a> share price is drawing attention following a large block deal in which Sepia Investments, an affiliate of private equity major ChrysCapital, sold a meaningful chunk of its holding in the pharmaceutical company. The transaction, which saw institutional buyers step in at a fairly tight price band, offers a useful window into how large private equity exits typically play out in listed Indian companies.<\/p>\n

Click Here – Get Free Investment Predictions<\/a><\/strong><\/p>\n

According to exchange disclosures, Sepia Investments sold 24.85 lakh shares of Corona Remedies, equivalent to a 4.06 percent stake, for a total consideration of Rs 509.6 crore at a price of Rs 2,050.32 per share. This sale formed part of Sepia Investments’ larger holding, which stood at 12.68 percent of Corona Remedies as of June 2026, indicating that the private equity affiliate retains a substantial residual stake in the company even after this partial exit, an important detail for anyone tracking the Corona Remedies share price and its ownership structure going forward.<\/p>\n

On the buying side of the transaction, SBI Mutual Fund emerged as the largest acquirer, picking up 15.4 lakh shares, or a 2.51 percent stake in Corona Remedies, for approximately Rs 315.7 crore. Amundi Funds Asia Equity Concentrated also participated, purchasing 3.12 lakh shares for Rs 63.96 crore. Both institutional buyers transacted at a price of around Rs 2,050 per share, closely aligned with the price at which Sepia Investments exited, which suggests the block deal was executed at a fairly narrow spread rather than at a steep discount, a detail that offers some insight into how the market currently values the Corona Remedies share price.<\/p>\n

Block deals of this nature, where a private equity investor gradually reduces its stake through structured sales to institutional buyers, are a fairly common feature of the Indian equity markets, particularly for companies that had earlier received private equity funding before their public listing. The fact that established institutional names like SBI Mutual Fund and Amundi stepped in to absorb a meaningful portion of the sale is often viewed as a sign of continued institutional confidence in the underlying business, even as the original financial sponsor looks to monetise part of its investment.<\/p>\n

Explore Univest Screeners for More Stock Ideas<\/a><\/strong><\/p>\n

For investors tracking the Corona Remedies share price, it is worth understanding the broader context of why private equity investors like ChrysCapital, through affiliates such as Sepia Investments, periodically reduce their holdings in portfolio companies after a listing. Private equity funds typically operate with a defined investment horizon and are structurally required to return capital to their own limited partners over time, which means partial stake sales through the secondary market are a routine part of the private equity lifecycle rather than necessarily a signal about the company’s near-term prospects.<\/p>\n

That said, any large block deal involving a company’s shares, including this one involving the Corona Remedies share price, can create short-term volatility or overhang concerns among retail investors, particularly if the market perceives further stake sales as likely in the near future given Sepia Investments’ remaining 12.68 percent holding. Retail and other market participants would do well to focus on the company’s underlying fundamentals, such as revenue growth, profitability trends and sector positioning within the pharmaceutical space, rather than reacting purely to ownership-level transactions when forming a view on the Corona Remedies share price.<\/p>\n

Pharmaceutical companies in India have generally seen steady institutional interest given the sector’s relatively defensive characteristics and export-oriented growth opportunities, and the participation of large mutual fund houses in this particular transaction reinforces that broader sectoral interest. Investors evaluating the Corona Remedies share price going forward should keep an eye on future block deal disclosures, quarterly financial results, and any commentary from company management regarding growth plans, capacity expansion or new product launches that could influence the stock’s medium-term trajectory.<\/p>\n

Download the Univest iOS App<\/a><\/strong> or the Univest Android App<\/a><\/strong> to track markets on the go.<\/p>\n

The block deal involving Sepia Investments and Corona Remedies highlights a routine but noteworthy event in the company’s shareholding pattern, with strong institutional demand from SBI Mutual Fund and Amundi Funds absorbing the sale at a tight price band. While such transactions are a normal part of the private equity exit process, investors tracking the Corona Remedies share price should continue to focus on the company’s core business fundamentals when making investment decisions.<\/p>\n

Staying updated with Corona Remedies share price helps investors make better-informed decisions in a fast-moving market.<\/p>\n

Tracking Corona Remedies share price closely also allows traders to react quickly to fresh developments as they unfold.<\/p>\n

Many market participants check Corona Remedies share price updates every morning before placing fresh trades.<\/p>\n

Understanding the drivers behind Corona Remedies share price movements is a useful habit for any serious investor.<\/p>\n

Financial news platforms and brokerage research desks routinely publish updates on Corona Remedies share price for this reason.<\/p>\n

Staying updated with Corona Remedies share price helps investors make better-informed decisions in a fast-moving market.<\/p>\n

Tracking Corona Remedies share price closely also allows traders to react quickly to fresh developments as they unfold.<\/p>\n

Univest is a SEBI-registered Research Analyst (Registration No. INH000013776). The content above is for informational and educational purposes only and does not constitute investment advice or a recommendation to buy or sell any security. Please verify all data independently and consult a qualified financial advisor before making any investment decisions. Investments in securities are subject to market risks.<\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n